Cash Position & Operating Runway: As of December 31, 2024, ARS Pharma had cash, cash equivalents, and short-term investments of $314.0 million, with 97,954,172 shares of common stock outstanding. The ...

For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H 1-antihistamines, administration of the oral, highly selective Bruton's tyrosine kinase ...

She was then on the administration of omalizumab subcutaneously at 300mg/day at a four-week interval. After 4 cycles of omalizumab treatment, oral tripterygium wilfordii tablets was tapered gradually ...

Phase III REMIX-1 and REMIX-2 trials demonstrated that remibrutinib, an oral BTK inhibitor, significantly reduced chronic spontaneous urticaria symptoms in patients unresponsive to second-generation ...

Patients with chronic spontaneous urticaria typically receive second-generation H 1-antihistamines as first-line therapy, but more than 50% continue to have symptoms. New research findings on ...

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of these symptoms) for more than 6 weeks. Remibrutinib, an oral ...

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

The patient was diagnosed with nonimmunologic contact urticaria from curcumin. Her employment duties were modified so that she could avoid the powder, and her symptoms improved, but she could ...

Atopic dermatitis (AD) is an inflammatory skin disorder. The pathogenesis is a complex interaction between environmental factors and genetic predisposition, The overall aim is to improve the ...